Citations

Clear

1526 citation(s) found for "Sun, Bo".

Oral Health Care for Children and Youth With Developmental Disabilities: Clinical Report
Sarvas, Elise , Webb, Jessica , Landrigan‐Ossar, Mary, Yin, Larry , HEALTH, SECTION ON ORAL, Beyer, Eric L., Brooks, Chevon, Feldman, Lauren , Kimball, C E, Tate, Anupama Rao , Unkel, John H. , Zaborowski, Matt, Crespin, Matt, Moursi, Amr M. , Beskin, Kera , Agrawal, Rishi , Bell, Deanna S. , Foster, Jessica E.A., Fremion, Ellen , Frierson, Sheryl, Melicosta, Michelle, Saunders, Barbara S. , Srivastava, Siddharth , Vargus‐Adams, Jilda , Kuo, Dennis Z. , Brosco, Jeffrey P. , Sadof, Matthew , Ware, Allysa , Yeargin-Allsopp, Marshalyn, Poon, Jennifer, Yeargin-Allsopp, Marshalyn, Kuznetsov, Alexandra , MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Chatterjee, Debnath , Diaz, Christina D. , Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan-Ossar, Mary, Fehr, James J. , Lin, Yuan‐Chi, Riefe, Jennifer, Sarvas, Elise W , HEALTH, SECTION ON ORAL, Karp, Jeffrey M. , Kimball, C. Eve, Sokal‐Gutierrez, Karen , Noritz, Garey H. , Zuckerman, Katharine E. , Weitzman, Carol Cohen , Yeargin-Allsopp, Marshalyn, Yeargin-Allsopp, Marshalyn, MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Long, Justin, Landrigan-Ossar, Mary, Adler, Adam C.

Mayo Clinic

Pediatrics | July 22, 2024 | Volume: 154 | Issue: 2 | Pages: No page available

10.1542/peds.2024-067603 | PMID 39034828 Get It

Oral health is an essential component of overall health for all individuals. The oral health of children and youth with developmental disabilities (CYDD) involves unique characteristics and needs of which pediatricians and pediatric clinicians can be aware. Risk for oral disease in CYDD is multifactorial and includes underlying medical conditions, medications, and ability to participate in preventive oral health care and treatment, and lack of access to providers is common for this population despite being eligible for Medicaid. Pediatric clinicians are uniquely positioned to support the oral health needs of CYDD and their families through the medical home. This clinical report aims to inform pediatric clinicians about the unique oral health needs of CYDD. It provides guidance on assessing caries risk and periodontal status using structured screening instruments; understanding dental trauma, the role of diet and caries risk, trauma prevention, and malocclusion; and providing anticipatory guidance on oral hygiene that includes tooth brushing, use of fluoridated toothpaste, assessing community water fluoridation, advocating for a dental home by 1 year of age, and transition to adult dental care as part of adolescent health care. It also highlights special considerations for dental treatment rendered under sedation or general anesthesia that CYDD may need. Pediatric clinicians can help reduce risk of CYDD developing dental disease by understanding the unique needs of their patients and their barriers to accessing oral health care in their community, communicating with the child’s dental home, and advocating for safe and accessible dental procedures.
Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis—methylomics of cholestatic liver disease
Juran, Brian D., McCauley, Bryan M. , Atkinson, Elizabeth J. , Schlicht, Erik M., Bianchi, Jackie K., Vollenweider, Jason, Ye, Hong , LaRusso, Nicholas F. , Gores, Gregory J. , Sun, Zhifu , Gores, Gregory J. , Vollenweider, Jason M, Sun, Zhifu , LaRusso, Nicholas F , Lazaridis, Konstantinos N.

Mayo Clinic

Hepatology Communications | July 18, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000496 | PMID 39023332 Get It

Background: The epigenome, the set of modifications to DNA and associated molecules that control gene expression, cellular identity, and function, plays a major role in mediating cellular responses to outside factors. Thus, evaluation of the epigenetic state can provide insights into cellular adaptions occurring over the course of disease. Methods: We performed epigenome-wide association studies of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) using the Illumina MethylationEPIC Bead Chip. Results: We found evidence of increased epigenetic age acceleration and differences in predicted immune cell composition in patients with PSC and PBC. Epigenetic profiles demonstrated differences in predicted protein levels including increased levels of tumor necrosis factor receptor superfamily member 1B in patients with cirrhotic compared to noncirrhotic PSC and PBC. Epigenome-wide association studies of PSC discovered strongly associated 5′-C-phosphate-G-3′ sites in genes including vacuole membrane protein 1 and SOCS3, and epigenome-wide association studies of PBC found strong 5′-C-phosphate-G-3′ associations in genes including NOD-like receptor family CARD domain containing 5, human leukocyte antigen-E, and PSMB8. Analyses identified disease-associated canonical pathways and upstream regulators involved with immune signaling and activation of macrophages and T-cells. A comparison of PSC and PBC data found relatively little overlap at the 5′-C-phosphate-G-3′ and gene levels with slightly more overlap at the level of pathways and upstream regulators. Conclusions: This study provides insights into methylation profiles of patients that support current concepts of disease mechanisms and provide novel data to inspire future research. Studies to corroborate our findings and expand into other -omics layers will be invaluable to further our understanding of these rare diseases with the goal to improve and individualize prognosis and treatment.
Comparative single-cell analysis reveals IFN-γ as a driver of respiratory sequelae after acute COVID-19
Li, Chaofan , Qian, Wei , Wei, Xiaoqin , Narasimhan, Harish , Wu, Yue , Arish, Mohd , Cheon, In Su , Tang, Jinyi , Santos, Gislane de Almeida , Sharifi, Kamyar , Kern, Ryan , Vassallo, Robert , de Almeida Santos, Gislane , Sharifi, Kamyar , Kern, R , Vassallo, Robert , Sun, Jie , Tang, J , Li, Chaofan , Li, Ying , Sun, Jie

Mayo Clinic

Science Translational Medicine | July 17, 2024 | Volume: 16 | Issue: 756 | Pages: No page available

10.1126/scitranslmed.adn0136 | PMID 39018367 Get It

Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) represent an urgent public health challenge and are estimated to affect more than 60 million individuals globally. Although a growing body of evidence suggests that dysregulated immune reactions may be linked with PASC symptoms, most investigations have primarily centered around blood-based studies, with few focusing on samples derived from affected tissues. Furthermore, clinical studies alone often provide correlative insights rather than causal mechanisms. Thus, it is essential to compare clinical samples with relevant animal models and conduct functional experiments to understand the etiology of PASC. In this study, we comprehensively compared bronchoalveolar lavage fluid single-cell RNA sequencing data derived from clinical PASC samples and a mouse model of PASC. This revealed a pro-fibrotic monocyte-derived macrophage response in respiratory PASC, as well as abnormal interactions between pulmonary macrophages and respiratory resident T cells, in both humans and mice. Interferon-γ (IFN-γ) emerged as a key node mediating the immune anomalies in respiratory PASC. Neutralizing IFN-γ after the resolution of acute SARS-CoV-2 infection reduced lung inflammation and tissue fibrosis in mice. Together, our study underscores the importance of performing comparative analysis to understand the cause of PASC and suggests that the IFN-γ signaling axis might represent a therapeutic target.
Psychiatric Disorders Among 5,800 Patients With Microscopic Colitis: A Nationwide Population-Based Matched Cohort Study
Bergman, David , Roelstraete, Björn , Sun, Jiangwei , Ebrahimi, Fahim , Butwicka, Agnieszka , Pardi, Darrell S. , Ludvigsson, Jonas F.

Mayo Clinic

American Journal of Gastroenterology | July 12, 2024 | Volume: 119 | Issue: 12 | Pages: 2516-2525

10.14309/ajg.0000000000002955 | PMID 38994845 Get It

INTRODUCTION: Microscopic colitis (MC) is an inflammatory condition of the large intestine. Primarily diagnosed in middle-aged and older adults, the incidence of the disease has increased markedly during the past few decades. While MC is associated with a reduced quality of life, large-scale studies on the association with future psychiatric disorders are lacking. METHODS: We conducted a nationwide matched cohort study in Sweden from 2006 to 2021. Through a nationwide histopathology database (the Epidemiology Strengthened by histoPathology Reports in Sweden study), we identified 5,816 patients with a colorectal biopsy consistent with MC. These patients were matched with 21,509 reference individuals from the general population all of whom with no previous record of psychiatric disorders. RESULTS: From 2006 to 2021, 519 patients with MC (median age 64.4 years [interquartile range = 49.5–73.3]) and 1,313 reference individuals were diagnosed with psychiatric disorders (9.9 vs 6.5 events per 1,000 person-years), corresponding to 1 extra case of psychiatric disorder in 29 patients with MC over 10 years. After adjustments, the hazard ratio for psychiatric disorders was 1.57 (95% confidence interval = 1.42–1.74). We found significantly elevated estimates up to 10 years after MC diagnosis and a trend toward higher risk with increasing age. Specifically, we observed increased risks for unipolar depression, anxiety disorders, stress-related disorders, substance abuse, and suicide attempts. In sibling-controlled analysis, the adjusted hazard ratio was 1.76 (95% confidence interval = 1.44–2.15). DISCUSSION: Patients with MC are at increased risk of incident psychiatric disorders compared with the general population.
Influenza Vaccination Mediates SARS-CoV-2 Spike Protein Peptide-Induced Inflammatory Response via Modification of Histone Acetylation
Zuo, Zejie , Mu, Yating , Qi, Fangfang , Zhang, Hongyang , Li, Zhihui , Zhou, Tuo , Guo, Wenhai , Guo, Kaihua , Hu, Xuezhu , Yao, Zhibin , Qi, Fangfang , Li, Zhihui , Hu, Xiquan

Mayo Clinic

Vaccines | July 2, 2024 | Volume: 12 | Issue: 7 | Pages: 731

10.3390/vaccines12070731 | PMID 39066369 Get It

The effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain rapidly wanes over time. Growing evidence from epidemiological studies suggests that influenza vaccination is associated with a reduction in the risk of SARS-CoV-2 infection and COVID-19 severity. However, the underlying mechanisms remain elusive. Here, we investigate the cross-reactive immune responses of influenza vaccination to SARS-CoV-2 spike protein peptides based on in vitro study. Our data indicate enhanced activation-induced-marker (AIM) expression on CD4+ T cells in influenza-vaccination (IV)-treated peripheral blood mononuclear cells (PBMCs) upon stimulation with spike-protein-peptide pools. The fractions of other immune cell subtypes, including CD8+ T cells, monocytes, NK cells, and antigen-presenting cells, were not changed between IV-treated and control PBMCs following ex vivo spike-protein-peptide stimulation. However, the classical antiviral (IFN-γ) and anti-inflammatory (IL-1RA) cytokine responses to spike-protein-peptide stimulation were still enhanced in PBMCs from both IV-immunized adult and aged mice. Decreased expression of proinflammatory IL-1β, IL-12p40, and TNF-α is associated with inhibited levels of histone acetylation in PBMCs from IV-treated mice. Remarkably, prior immunity to SARS-CoV-2 does not result in modification of histone acetylation or hemagglutinin-protein-induced cytokine responses. This response is antibody-independent but can be mediated by manipulating the histone acetylation of PBMCs. These data experimentally support that influenza vaccination could induce modification of histone acetylation in immune cells and reveal the existence of potential cross-reactive immunity to SARS-CoV-2 antigens, which may provide insights for the adjuvant of influenza vaccine to limit COVID-19-related inflammatory responses.
STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Chen, Jinghong , Zhu, Lingxuan , Zeng, Dongqiang , Qi, Chang , Tang, Bufu , Shi, Wenjie , Guo, Shipeng, Sun, Xu , Ngo, Trunghieu, Pu, Zhongji , He, Yongbin, Wu, Haiyang , Cheungpasitporn, Wisit, Huang, Haojie , Wang, Shixiang , Cabannes, Loïc, Ren, Gerald Sng Gui , Ali, Stephen R , Cheng, Quan, Miao, Kai , Mou, Weiming , Lin, Anqi , Zeng, Dongqiang, Liu, Zaoqu , Jiang, Aimin , Shi, Wenjie, Kahlert, Ulf D. , Zhou, Jian‐Guo , Lu, Xiaofan , Jia, Baolei , Jeon, Che Ok , Gu, Shuqin , Cheungpasitporn, Wisit , Mao, Weipu , Chen, Xin , Cabannes, Loïc, Whitaker, Iain Stuart , Cheng, Quan, Yuan, Shuofeng , Luo, Peng

Mayo Clinic

iMetaOmics | July 2, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/imo2.7 | PMID 41675544 Get It

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial for ensuring reliable and consistent evaluation of generative AI in healthcare. Our objective is to develop robust, standardized guidelines tailored for evaluating generative AI performance in medical contexts. Through a rigorous literature review utilizing the Web of Sciences, Cochrane Library, PubMed, and Google Scholar, we focused on research testing generative AI capabilities in medicine. Our multidisciplinary team of experts conducted discussion sessions to develop a comprehensive 32‐item checklist. This checklist encompasses critical evaluation aspects of generative AI in medical applications, addressing key dimensions such as question collection, querying methodologies, and assessment techniques. The checklist and its broader assessment framework provide a holistic evaluation of AI systems, delineating a clear pathway from question gathering to result assessment. It guides researchers through potential challenges and pitfalls, enhancing research quality and reporting and aiding the evolution of generative AI in medicine and life sciences. Our framework furnishes a standardized, systematic approach for testing generative AI's applicability in medicine. For a concise checklist, please refer to Table S or visit GenAIMed.org .
Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer
Tian, Chunfang , Jing, Haiyan , Wang, Jinshen , Gao, Binbin, Sun, Xiaogang , Song, Wei , Sha, Dan , Tian, Chun-Fang , Yao, Zhi-Gang , Saberzadeh-Ardestani, Bahar , Sha, Dan , Sinicrope, Frank A. , Li, Leping

Mayo Clinic

The Oncologist | June 22, 2024 | Volume: 29 | Issue: 10 | Pages: e1280-e1290

10.1093/oncolo/oyae124 | PMID 38907674 Get It

Abstract Background Tumor microenvironment (TME) characteristics including tumor stroma ratio (TSR), tumor budding (TB), and tumor-infiltrating lymphocytes (TILs) were examined in resected gastric cancer. These TME features have been shown to indicate metastatic potential in colon cancer, and intestinal-type gastric cancer (IGC) has pathological similarities with that malignancy. Methods TSR, TB, and TILs were quantified in routine histological sections from 493 patients with IGC who underwent radical resection at 2 university hospitals in China from 2010 to 2016. TME variables were dichotomized as follows: TSR (50%), TILs (median), TB per international guidelines (4 buds/0.785mm2), and platelet-lymphocyte ratio (PLR) per survival ROC. Association of TME features with patient clinicopathological characteristics, time-to-recurrence (TTR), and cancer-specific-survival (CSS) were examined using univariate and multivariate analysis, including a relative contribution analysis by Cox regression. Results Patients whose tumors showed high TSR or high TB or low TILs were each significantly associated with increased T and N stage, higher histological grade, and poorer TTR and CSS at 5 years. Only TSR and N stage were independently associated with TTR and CSS after adjustment for covariates. PLR was only independently associated with TTR after adjustment for covariates. Among the variables examined, only TSR was significantly associated with both TTR (HR 1.72, 95% CI, 1.14-2.60, P = .01) and CSS (HR 1.62, 95% CI, 1.05-2.51, P = .03) multivariately. Relative contribution to TTR revealed that the top 3 contributors were N stage (45.1%), TSR (22.5%), and PLR (12.9%), while the top 3 contributors to CSS were N stage (59.9%), TSR (14.7%), and PLR (10.9%). Conclusions Among the examined TME features, TSR was the most robust for prognostication and was significantly associated with both TTR and CSS. Furthermore, the relative contribution of TSR to patient TTR and CSS was second only to nodal status.
Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy
Bressler, Neil M. , Bakri, Sophie J. , Brittain, Christopher , Pickthorn, Karen, Lin, Hugh, Sun, Christy, Martin, Jillian , Freund, K. Bailey , Kim, Judy E. , Ferrara, Daniela , Pickthorn, Karen

Mayo Clinic

JAMA Ophthalmology | June 20, 2024 | Volume: 142 | Issue: 8 | Pages: 772

10.1001/jamaophthalmol.2024.2061 | PMID 38900484 Get It

ImportanceIntraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved intravitreous agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL intravitreous injections may result in IOP-related complications.ObjectiveTo investigate the effect of 1 year of repeated 0.1-mL intravitreous injections on IOP outcomes.Design, Setting, and ParticipantsThis study was a post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration. Both trials were conducted between 2014 and 2018 and recruited participants who were 50 years or older and had bilateral geographic atrophy. This post hoc analysis was performed between 2018 and 2022.InterventionsIntravitreous lampalizumab, 0.1 mL, every 4 weeks; lampalizumab, 0.1 mL, every 6 weeks; or sham procedure every 4 weeks or 6 weeks for 48 weeks.Main Outcomes and MeasuresIOP changes in the 4-week-frequency study arms and ocular adverse events to week 48 in all arms. The hypothesis for this analysis was formulated after data collection.ResultsAmong a total of 1851 participants, there was no change in mean pre-injection IOP values through 48 weeks in either arm. The adverse events glaucoma and ocular hypertension were reported for 1.8% of participants treated with lampalizumab and 1.6% of those in the sham arm.Conclusions and RelevanceOver 1 year, IOP increases were rare and did not affect treated participants more frequently than sham arm participants. These findings support the low risk of persistent IOP increases, on average, of intravitreous 0.1-mL injection volumes administered for 1 year in a manner similar to that performed in these clinical trials. These results may be valuable in the design of future therapeutic trials considering this volume for injections particularly as more recently approved agents use volumes of 0.07 to 0.1 mL.Trial RegistrationClinicalTrials.gov Identifiers: NCT02247479 and NCT02247531
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.